









Markets
/
Stocks
/
nasdaq-ntrb
/

Nutriband Inc

NTRB

7.220USD

-0.040-0.55%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

79.96MMarket Cap

LossP/E TTM



Nutriband Inc

7.220

-0.040-0.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

68 / 207

Overall Ranking

155 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

15.000

Target Price

+106.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.14M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 133.81.

Undervalued

The company’s latest PE is -7.97, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.87M shares, increasing 5.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 199.63K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.68.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.11, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 622.45K, representing a year-over-year increase of 40.56%, while its net profit experienced a year-over-year increase of 1296.36%.

Score

Industry at a Glance

Previous score

6.11

Change



Financials

9.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.63

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

3.37

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.15

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -8.01, which is -39.37% below the recent high of -4.86 and 13.09% above the recent low of -6.97.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Nutriband Inc is 15.00, with a high of 15.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

15.000

Target Price

+106.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Nutriband Inc

NTRB

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.31, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 7.96 and the support level at 6.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.31

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.285

Neutral

RSI(14)

57.318

Neutral

STOCH(KDJ)(9,3,3)

76.905

Neutral

ATR(14)

0.538

Low Volatility

CCI(14)

95.305

Neutral

Williams %R

20.319

Buy

TRIX(12,20)

0.048

Sell

StochRSI(14)

89.104

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

7.058

Buy

MA10

6.771

Buy

MA20

6.577

Buy

MA50

7.068

Buy

MA100

7.060

Buy

MA200

6.438

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 79.52%, representing a quarter-over-quarter increase of 8.72%. The largest institutional shareholder is The Vanguard, holding a total of 199.63K shares, representing 1.66% of shares outstanding, with 47.86% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Botgros (Vitalie)

3.09M

+30.22%

TII Jet Services, LDA

1.81M

+36.66%

Sheridan (Gareth)

1.76M

-0.01%

Glinka (Serguei)

825.00K

Melnik (Serguei)

820.42K

The Vanguard Group, Inc.

Star Investors

199.03K

+59.75%

Goodman (Gerald)

86.33K

Geode Capital Management, L.L.C.

63.55K

+1.79%

Smith (Allan)

41.91K

-14.29%

Patrick (Jeff)

36.61K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.23, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.